Barclays
COLL icon

Barclays’s Collegium Pharmaceutical COLL Stock Holding History

Barclays’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.38M Sell
71,949
-31,660
-31% -$1.34M ﹤0.01% 2236
2025
Q4 		$4.8M Buy
103,609
+29,578
+40% +$1.24M ﹤0.01% 2249
2025
Q3 		$2.59M Sell
74,031
-15,403
-17% -$535K ﹤0.01% 2686
2025
Q2 		$2.64M Buy
89,434
+15,731
+21% +$449K ﹤0.01% 2629
2025
Q1 		$2.2M Sell
73,703
-6,051
-8% -$185K ﹤0.01% 2564
2024
Q4 		$2.28M Buy
79,754
+4,702
+6% +$156K ﹤0.01% 2780
2024
Q3 		$2.9M Buy
75,052
+45,291
+152% +$1.62M ﹤0.01% 2544
2024
Q2 		$958K Sell
29,761
-17,403
-37% -$603K ﹤0.01% 2620
2024
Q1 		$1.83M Sell
47,164
-25,568
-35% -$895K ﹤0.01% 2643
2023
Q4 		$2.24M Buy
72,732
+33,139
+84% +$830K ﹤0.01% 2821
2023
Q3 		$885K Buy
39,593
+5,713
+17% +$130K ﹤0.01% 2417
2023
Q2 		$728K Sell
33,880
-769
-2% -$17.5K ﹤0.01% 2522
2023
Q1 		$831K Buy
34,649
+4,427
+15% +$117K ﹤0.01% 2878
2022
Q4 		$701K Buy
30,222
+3,886
+15% +$78.4K ﹤0.01% 3070
2022
Q3 		$423K Sell
26,336
-15,007
-36% -$265K ﹤0.01% 2798
2022
Q2 		$732K Sell
41,343
-7,683
-16% -$129K ﹤0.01% 2581
2022
Q1 		$998K Sell
49,026
-23,565
-32% -$445K ﹤0.01% 2399
2021
Q4 		$1.36M Sell
72,591
-11,569
-14% -$226K ﹤0.01% 2625
2021
Q3 		$1.66M Buy
84,160
+33,747
+67% +$730K ﹤0.01% 2476
2021
Q2 		$1.19M Sell
50,413
-23,229
-32% -$537K ﹤0.01% 2545
2021
Q1 		$1.75M Buy
73,642
+62,394
+555% +$1.48M ﹤0.01% 2396
2020
Q4 		$225K Sell
11,248
-4,547
-29% -$88.8K ﹤0.01% 3695
2020
Q3 		$328K Sell
15,795
-3,137
-17% -$56.6K ﹤0.01% 3523
2020
Q2 		$331K Buy
18,932
+8,055
+74% +$158K ﹤0.01% 3652
2020
Q1 		$178K Sell
10,877
-21,284
-66% -$439K ﹤0.01% 4396
2019
Q4 		$662K Buy
32,161
+7,753
+32% +$129K ﹤0.01% 4048
2019
Q3 		$280K Buy
24,408
+2,108
+9% +$24.1K ﹤0.01% 4714
2019
Q2 		$293K Sell
22,300
-29,557
-57% -$395K ﹤0.01% 4776
2019
Q1 		$786K Buy
51,857
+14,150
+38% +$227K ﹤0.01% 3671
2018
Q4 		$648K Buy
37,707
+26,688
+242% +$457K ﹤0.01% 3568
2018
Q3 		$162K Buy
11,019
+4,709
+75% +$83.5K ﹤0.01% 5173
2018
Q2 		$150K Sell
6,310
-4,447
-41% -$109K ﹤0.01% 4965
2018
Q1 		$276K Buy
10,757
+5,713
+113% +$136K ﹤0.01% 4540
2017
Q4 		$93K Buy
5,044
+4,518
+859% +$64.7K ﹤0.01% 5292
2017
Q3 		$6K Buy
526
+291
+124% +$3.21K ﹤0.01% 6330
2017
Q2 		$3K Sell
235
-5,856
-96% -$57.9K ﹤0.01% 6332
2017
Q1 		$62K Sell
6,091
-10,516
-63% -$156K ﹤0.01% 5204
2016
Q4 		$258K Buy
16,607
+5,299
+47% +$88.1K ﹤0.01% 3994
2016
Q3 		$218K Buy
11,308
+10,994
+3,501% +$131K ﹤0.01% 3905
2016
Q2 		$4K Buy
314
+200
+175% +$3.3K ﹤0.01% 5779
2016
Q1 		$2K Sell
114
-210
-65% -$3.82K ﹤0.01% 5855
2015
Q4 		$9K Buy
324
+289
+826% +$6.09K ﹤0.01% 5428
2015
Q3 		$1K Sell
35
-93
-73% -$1.68K ﹤0.01% 6509
2015
Q2 		$2K Buy
+128
New +$2.21K ﹤0.01% 6784

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Barclays's COLL Position: Q1 2026 in Review

Barclays reduced its Collegium Pharmaceutical (COLL) stake by 31% in Q1 2026, selling an estimated $1.34M and leaving 71,949 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Barclays first reported a position in COLL in Q2 2015 and has held it in 44 quarters since. The position peaked at $4.8M in Q4 2025. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Barclays held 71,949 shares of Collegium Pharmaceutical worth $2.38M as of Q1 2026.
  • Barclays sold 31,660 Collegium Pharmaceutical shares in Q1 2026, an estimated $1.34M.
  • Collegium Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2236 holding.
  • Barclays first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 44 quarters since.
  • Barclays's Collegium Pharmaceutical position peaked at $4.8M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.